Learn More About Hereditary Angioedema
About 1 in 50,000 people are affected by HAE. A patient’s specific type of hereditary angioedema can be determined by the level of a protein, called C1 inhibitor, in their bloodstream. About 85 percent have Type 1. Type 2 makes up about 15 percent of cases. Type 3 is extremely rare. All three types have similar signs and symptoms.
Although HAE is usually inherited, it can occur from new gene mutations with no family history. Symptoms usually begin in childhood, getting more intense during puberty. The frequency and duration of attacks varies. In general, they last 3–4 days and happen about once every 1–2 weeks.
There are multiple treatments on the market today to treat or prevent HAE attacks, most of which can be self-administered. Diplomat Specialty Infusion Group offers multiple HAE treatments, including Berinert® (C1 esterase inhibitor [human]) and Firazyr® (icatibant injection).
The information contained herein may not be construed as medical advice. It is for educational purposes only. Diplomat Pharmacy Inc. takes no responsibility for the accuracy or validity of the information contained herein, nor the claims or statements of any manufacturer.